We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+31.13%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.73B
AUM Growth
+$575M
Cap. Flow
-$186M
Cap. Flow %
-3.94%
Top 10 Hldgs %
46.08%
Holding
127
New
17
Increased
23
Reduced
25
Closed
19

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$95.5M
2
VKTX icon
Viking Therapeutics
VKTX
+$57.4M
3
ARGX icon
argenx
ARGX
+$52.2M
4
ADGM
Adagio Medical Holdings
ADGM
+$46.7M
5
ORKA
Oruka Therapeutics
ORKA
+$43M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$441M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$60M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$38.8M
5
SWTX
SpringWorks Therapeutics
SWTX
+$35.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
76
CALL
DELISTED
Verona Pharma
VRNA
$7.19M 0.15%
+250,000
New +$6.15M
VRNA
77
PUT
DELISTED
Verona Pharma
VRNA
$7.19M 0.15%
+250,000
New +$6.15M
AMLX icon
78
Amylyx Pharmaceuticals
AMLX
$4.17B
$6.89M 0.15%
+2,125,649
New +$4.78M
BCYC
79
Bicycle Therapeutics
BCYC
$307M
$5.79M 0.12%
255,994
-316,006
-55% -$7.29M
VERU icon
80
Veru
VERU
$46.2M
$5.6M 0.12%
728,316
+21,988
+3% +$190K
FLNA
81
PUT
Filana Therapeutics
FLNA
$45.8M
$5.39M 0.11%
183,000
– –
FULC icon
82
CALL
Fulcrum Therapeutics
FULC
$295M
$5.36M 0.11%
+1,500,000
New +$11.1M
BBOT
83
BridgeBio Oncology
BBOT
$751M
$5.22M 0.11%
500,000
– –
BDSX icon
84
Biodesix
BDSX
$296M
$3.87M 0.08%
108,694
– –
DTIL icon
85
Precision BioSciences
DTIL
$236M
$3.82M 0.08%
426,293
– –
MREO
86
Mereo BioPharma
MREO
$45M
$3.35M 0.07%
815,722
-437,528
-35% -$1.81M
LYRA
87
DELISTED
LYRA THERAPEUTICS INC
LYRA
$3.28M 0.07%
255,151
– –
NBTX
88
Nanobiotix
NBTX
$2.11B
$3.19M 0.07%
555,066
– –
ABSI icon
89
Absci
ABSI
$1.65B
$2.67M 0.06%
700,000
– –
LONA
90
LeonaBio Inc
LONA
$75.5M
$2.41M 0.05%
540,296
– –
XFOR icon
91
X4 Pharmaceuticals
XFOR
$412M
$2.37M 0.05%
118,182
– –
NVNO
92
enVVeno Medical
NVNO
$7.5M
$2.33M 0.05%
19,838
+2,029
+11% +$373K
KYMR icon
93
Kymera Therapeutics
KYMR
$10.5B
$2.19M 0.05%
+46,213
New +$2.04M
TRIB
94
Trinity Biotech
TRIB
$7.9M
$1.98M 0.04%
60,000
– –
PYXS icon
95
Pyxis Oncology
PYXS
$255M
$1.87M 0.04%
+508,462
New +$1.78M
IRTC icon
96
iRhythm Holdings
IRTC
$4.06B
$1.68M 0.04%
22,591
-12,614
-36% -$1M
GPCR icon
97
Structure Therapeutics
GPCR
$3.56B
$1.53M 0.03%
34,852
– –
LXEO icon
98
Lexeo Therapeutics
LXEO
$421M
$1.26M 0.03%
+139,835
New +$1.67M
NVAX icon
99
PUT
Novavax
NVAX
$1.56B
$1.26M 0.03%
100,000
– –
FATE icon
100
Fate Therapeutics
FATE
$306M
$1.21M 0.03%
345,575
– –
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Perceptive Advisors held 127 positions worth $4.73B, up 14% from $4.15B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $186M in Q3 2024, closing 19 positions and reducing 25 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $441M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Adagio Medical Holdings worth $25.3M.

  • Perceptive Advisors's largest Q3 2024 buy was Adagio Medical Holdings: 9,812,419 shares worth $25.3M.
  • Perceptive Advisors added most to Verona Pharma in Q3 2024, an estimated $95.5M increase.
  • Perceptive Advisors's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $60M.
  • Perceptive Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $441M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $4.73B portfolio in Q3 2024.
  • Perceptive Advisors opened 17 new positions and closed 19 in Q3 2024.
  • Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $4.73B.

Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.